SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with cizutamig (BCMA TCE) and CND261 (CD20 TCE). Clinical evaluation is ongoing under multiple active INDs, investigator-initiated trials and compassionate use across ten clinical indications. “In 2024, we started Candid with a hypothesis that TCE
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
